All In Biotech

Drug Trial Radar · NCT07142044

Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Nov 1, 2025

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Lead sponsor
EicOsis Human Health Inc.Industry
Sponsor type
Industry
Collaborators
University of California, Davis; Michael J. Fox Foundation for Parkinson's Research
First posted
Aug 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the oral drug candidate EC5026 is safe and targets the correct pathways to treat Parkinson's Disease in adults. It will also learn about the levels of drug that are achieved in blood and in the fluid surrounding the brain (spinal fluid). The main questions it aims to answer are: * Is EC5026 safe in adults with Parkinson's Disease? * What are the levels of EC5026 achieved after oral administration for 28 days? * What molecules or pathways does EC5026 target, and to what extent? In addition, although it is not one of the primary aims of the study, this clinical trial will also explore if oral administration of EC5026 improves the symptoms of Parkinson's Disease. Researchers will compare EC5026 to a placebo (a look-alike substance that contains no drug). Participants will: * Take EC5026 or a placebo every day for 28 consecutive days * Visit the clinic for frequent checkups, blood tests, spinal fluid tests, and questionnaires

Conditions

  • Parkinson's Disease (PD)

Interventions

  • EC5026 oral tabletDrug

    Oral soluble epoxide hydrolase inhibitor

  • PlaceboDrug

    Matching oral placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAE) [Safety and Tolerability]Time frame: 56 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California Davis

    Sacramento, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.